German-Austrian coalition of scientists creating a ribosome-based cell therapy platform. Pushing the boundaries of the possibilities of modern biotechnology and our understanding of the genetic mechanisms of disease cognition, KBHB has submitted its Project to Babu™ to use the newly created platform to treat a rare and incurable disease, epidermolysis bullosa ( Latin epidermolysis bullosa, EB). This disease, or more specifically its variant EBJ, ends in the early death of a child, rarely allowing affected young patients to live to adulthood. Only 1,000 patients worldwide suffer from this variant of EB, and Babu™ has taken on the task of helping to see this Project through to completion.